Smith & Nephew enters $8.5M stem cell R&D accord
Scientists at the Smith & Nephew Research Centre in York, UK, have launched an R&D collaboration with the Regenerative Medicine Institute (REMEDI) at the National University of Ireland Galway, to develop new therapies using adult bone marrow stem cells to promote regrowth of healthy cartilage and repair damaged joints. The 6.0 million-euro ($8.5 million) project is backed by the Industrial Development Agency Ireland.
The Smith & Nephew Research Centre says it has already developed early prototype cell technologies, including the ability to grow human cartilage from adult stem cells.
According to the firm, the deal with REMEDI, which has extensive expertise in osteoarthritis cartilage repair, will speed up the process of producing viable new orthopedic therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze